United Therapeutics (UTHR, Financial), a biotechnology firm focused on developing treatments for pulmonary arterial hypertension, saw its stock price fall by 2.45%. The stock is currently trading at $399.95 with a trading volume of 212,335 shares and a turnover rate of 0.48%. The stock's price amplitude is recorded at 3.33%.
Recent earnings reports reveal that United Therapeutics generated $749 million in revenue, with a net income of $309 million, equating to an earnings per share of $6.93. The company's gross profit stands at $666 million, and it has a price-to-earnings ratio of 17.57. Among 17 rating institutions, 53% recommend buying, 35% advise holding, and 12% suggest selling the stock.
The broader biotechnology sector, where United Therapeutics operates, declined by 0.69%. Within this sector, stocks such as Cero Therapeutics Holdings, Inc., Aligos Therapeutics, Inc., and Lakeshore Biopharma Co., Ltd experienced significant gains. Cero Therapeutics Holdings, Inc., Revelation Biosciences, Inc., and Elevai Labs, Inc. showed notable activity with high turnover rates of 744.44%, 499.47%, and 242.80% respectively. Stocks like Cero Therapeutics Holdings, Inc., Aligos Therapeutics, Inc., and Lakeshore Biopharma Co., Ltd also demonstrated large amplitude movements, recording 132.14%, 72.42%, and 61.39%, respectively.
United Therapeutics focuses on therapies targeting the prostacyclin pathway for treating pulmonary arterial hypertension, a rare and progressive condition characterized by high blood pressure in the lungs. Though the company also markets a pediatric cancer drug, its primary emphasis is on pulmonary arterial hypertension research, with all sales occurring within the United States.
